Gilead Sciences News
News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.
3 hrs ago | Investor's Business Daily
The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline.
Trending on the Topix Network
8 hrs ago | The Motley Fool
Here are three things investors should pay attention to during the conference call.
9 hrs ago | Seeking Alpha
Pending data by year-end, we expect GILD to pay above fair value >100% upside for MGNX, reflecting its scarcity value delivering both immuno-oncology exposure and high-throughput drug development.
12 hrs ago | TheStreet.com
Survey: how high do $GILD 's Sovaldi sales need to be tomorrow to move the stock up? - Meg Tirrell July 22, 2014 .
16 hrs ago | Daily Press & Argus
But it also comes with a scary side effect: a price of $1,000 a pill. Because the pills must be taken once a day for 12 weeks, the cost of treatment comes to $84,000, plus thousands more for other drugs included in the protocol.
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued.
Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.
Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.
We all know Gilead Sciences' hepatitis C treatment, Sovalidi, has been a blockbuster.
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
The United States is unquestionably the premier economic superpower around the globe.
The best performing sector as of midday Friday is the Utilities sector, up 1.1%.
Stocks continued to add to broad gains in late trading Friday and were on pace to end modestly higher on the week.
Biotech stock stocks enter their earnings season with investors increasingly interested in the long-term outlook for product pipelines, although large-cap growth stocks remain central to the sectors performance, an analyst said Friday.
Updated: Tue Jul 22, 2014 06:38 pm
Copyright © 2014 Topix LLC